Table 3.
Lesion | Proportion of lesions (%) | |||||
---|---|---|---|---|---|---|
Monoclonal immunoglobulin deposits | Detectable monoclonal immunoglobulin | MM | MGRS | Othera | Refs | |
Light-chain cast nephropathy | 100 | 100 | 99 | 0 | ~1 | 2,4,11,13 |
Immunoglobulin-related amyloid amyloidosis | 96 | 99 | 16 | 80 | 1–4 | 43,113,128,129 |
MIDD | 100 | 100 | 0–20 | 78–100 | 1–2 | 29,31,68,130,131 |
Light-chain proximal tubulopathy | 100 | 97b | 12–33 | 61–80 | 3–8 | 32,56,58,132 |
Cryoglobulinaemic (type I) glomerulonephritis | 100 | 90–100 | 6–8 | 47–52 | 24–56 | 133–136 |
Cryoglobulinaemic (type II) glomerulonephritis | 100 | 49 | 0 | 20 | 7 | 133–136 |
PGNMID | 100 | 30–32 | 4 | 96 | ~1 | 24,72 |
Crystal-storing histiocytosis | 83 | 90 | 33 | 8 | 50 | 137 |
Cryocrystalglobulin or crystalglobulin nephropathy | 91 | 82 | 61 | 18 | 4 | 138 |
Immunotactoid glomerulonephritis | 69–93 | 63–71 | 0–13 | 25–50 | 25–50 | 23,51 |
C3 glomerulopathy with monoclonal gammopathyc | 0 | 28–83d | 0–40d | 40–90 | 6–10 | 25,74,75,104 |
Monoclonal fibrillary glomerulonephritise | 100 | 7–17 | 0–54 | 55–98 | 2–10 | 44,47,139 |
MGRS, monoclonal gammopathy of renal significance; MIDD, monoclonal immunoglobulin deposition disease; MM, multiple myeloma; PGNMID, proliferative glomerulonephritis with monoclonal immunoglobulin deposits. aHaematological conditions including lymphoplasmacytic lymphoma (Waldenström macroglobulinaemia), smouldering Waldenström macroglobulinaemia, B cell lymphomas, chronic lymphocytic lymphoma and monoclonal B cell lymphocytosis. bSensitivity increased by immunofluorescence after pronase digestion. cMost instances of fibrillary glomerulonephritis and C3 glomerulopathy are not associated with a monoclonal gammopathy. The percentages for MM, MGRS and other haematological conditions relate to the group of patients who do have a monoclonal gammopathy. dPatients over the age of 50 years. eIn these patients, the glomerular deposits show light-chain restriction or stain for IgG without light chains, both by frozen tissue and paraffin tissue immunofluorescence (as in 15–17% of patients with fibrillary glomerulonephritis).